Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Ramey

Allergy & Immunology North Charleston, SC Medical Doctor

NPI 1841260874 CMS profile 38615

7555 Northside Dr, North Charleston, SC 29420

Open in the dashboard

General payments

$126,366

514 records reported · program years 2019–2025

Research payments

$3,226

Paid to them · 29 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,356,064 paid to institutions, not to them · program years 2019–2025

Through program year 2025, John Ramey of North Charleston, SC is reported in the CMS Open Payments database as having received $126,366 across 514 general payments and $3,226 in research payments paid to them. Separately, studies naming them as principal investigator received $1,356,064 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,388 76
2025 Research $73 3
2024 General $11,363 66
2023 General $12,903 87
2023 Research $1,671 12
2022 General $31,262 81
2021 General $33,266 86
2020 General $7,556 47
2020 Research $1,482 14
2019 General $23,629 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Ramey
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to John Ramey were reported at $6,388. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year John Ramey Allergy & Immunology median Middle half National median
2019 $23,629 $594 $163–$1,512 $163
2020 $7,556 $426 $106–$1,233 $114
2021 $33,266 $638 $157–$1,708 $132
2022 $31,262 $790 $205–$1,961 $149
2023 $12,903 $852 $220–$2,147 $160
2024 $11,363 $865 $203–$2,267 $164
2025 $6,388 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $39,724 79 payments
  2. Novartis Pharmaceuticals Corporation $31,709 57 payments
  3. Genentech USA, Inc. $20,894 46 payments
  4. AstraZeneca Pharmaceuticals LP $20,432 88 payments
  5. Genzyme Corporation $4,662 64 payments
  6. Arcutis Biotherapeutics, Inc. $1,500 1 payment
  7. ALK-Abello, Inc $974 11 payments
  8. BioCryst Pharmaceuticals, Inc. $875 1 payment
  9. Pfizer Inc. $568 14 payments
  10. Regeneron Healthcare Solutions, Inc. $444 18 payments
  11. Other $4,584 135 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $82,875 41 payments
  2. Consulting Fee $17,975 10 payments
  3. Food and Beverage $13,488 427 payments
  4. Travel and Lodging $10,948 28 payments
  5. Honoraria $825 2 payments
  6. Education $254 6 payments
Products named General payments · program years 2019–2025
  1. NUCALA Immunology $34,989 51 payments
  2. Xolair Immunology $20,958 48 payments
  3. XOLAIR Respiratory $19,195 30 payments
  4. FASENRA Respiratory $14,002 39 payments
  5. DUPIXENT $5,873 103 payments
  6. FASENRA Respiratory $5,447 18 payments
  7. NUCALA Respiratory $4,413 14 payments
  8. Zoryve $1,500 1 payment
  9. TEZSPIRE Respiratory $575 19 payments
  10. TEZSPIRE Inflammation $409 14 payments
  11. Other $6,407 214 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $3,154 26 payments
  2. Teva Pharmaceuticals USA, Inc. $73 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

668

Median for Allergy/ Immunology: 449

Drug cost

$349,723

Median for Allergy/ Immunology: $169,700

Branded share of claims

49.3%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 25 $98,177
Tezspire Tezepelumab-Ekko Brand 20 $82,628
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 88 $63,160
Xolair Omalizumab Brand 12 $38,568
Breo Ellipta Fluticasone/Vilanterol Brand 31 $17,597
Spiriva Respimat Tiotropium Bromide Brand 23 $15,664
Arnuity Ellipta Fluticasone Furoate Brand 39 $11,351
Advair Hfa Fluticasone Propion/Salmeterol Brand 17 $6,608
Epinephrine Generic 21 $4,505
Qvar Redihaler Beclomethasone Dipropionate Brand 11 $3,710

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$145,675

Of which drugs: $85,560

Medicare patients

240

Average age 73

Services billed

7,879

158 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 52%
Diabetes 26%
Osteoporosis 24%
Ischemic heart disease 20%
Depression 18%
COPD 17%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 13 1,875 $55,934

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $1,705
$1,705 — —
DUPIXENT
  • GENZYME CORPORATION $294
  • SANOFI-AVENTIS U.S. LLC $134
  • Regeneron Healthcare Solutions, Inc. $82
$510 25 —
XOLAIR
  • Novartis Pharmaceuticals Corporation $130
  • Genentech USA, Inc. $102
$232 12 1,875
AYVAKIT
  • Blueprint Medicines Corporation $142
$142 — —
CUTAQUIG
  • Octapharma USA, Inc. $130
$130 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

543 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record